Serge Saxonov Sells 4,877 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock

10x Genomics, Inc. (NASDAQ:TXGGet Free Report) CEO Serge Saxonov sold 4,877 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total value of $118,511.10. Following the transaction, the chief executive officer now owns 889,641 shares in the company, valued at approximately $21,618,276.30. The sale was disclosed in a document filed with the SEC, which is available through this link.

Serge Saxonov also recently made the following trade(s):

  • On Monday, March 4th, Serge Saxonov sold 4,660 shares of 10x Genomics stock. The shares were sold at an average price of $44.00, for a total value of $205,040.00.

10x Genomics Stock Down 4.7 %

Shares of TXG traded down $1.12 during midday trading on Thursday, reaching $22.95. The company had a trading volume of 1,560,634 shares, compared to its average volume of 1,566,728. 10x Genomics, Inc. has a 1-year low of $22.80 and a 1-year high of $63.57. The stock has a market cap of $2.73 billion, a PE ratio of -10.29 and a beta of 1.94. The firm has a 50 day simple moving average of $31.01 and a 200-day simple moving average of $40.88.

10x Genomics (NASDAQ:TXGGet Free Report) last issued its earnings results on Tuesday, April 30th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.50). 10x Genomics had a negative return on equity of 30.85% and a negative net margin of 42.20%. The business had revenue of $141.01 million during the quarter, compared to the consensus estimate of $142.24 million. During the same period last year, the company earned ($0.44) EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. As a group, sell-side analysts anticipate that 10x Genomics, Inc. will post -1.55 earnings per share for the current fiscal year.

Institutional Trading of 10x Genomics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. UMB Bank n.a. increased its position in shares of 10x Genomics by 51.6% during the 4th quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after purchasing an additional 266 shares during the last quarter. Van ECK Associates Corp increased its position in shares of 10x Genomics by 23.4% during the 4th quarter. Van ECK Associates Corp now owns 1,908 shares of the company’s stock worth $107,000 after purchasing an additional 362 shares during the last quarter. AIA Group Ltd increased its position in shares of 10x Genomics by 0.9% during the 4th quarter. AIA Group Ltd now owns 41,369 shares of the company’s stock worth $2,315,000 after purchasing an additional 365 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in 10x Genomics by 113.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock valued at $26,000 after acquiring an additional 371 shares during the period. Finally, Treasurer of the State of North Carolina boosted its holdings in 10x Genomics by 1.0% during the 4th quarter. Treasurer of the State of North Carolina now owns 40,717 shares of the company’s stock valued at $2,279,000 after acquiring an additional 400 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TXG has been the topic of a number of recent analyst reports. TD Cowen lowered 10x Genomics from a “buy” rating to a “hold” rating and decreased their target price for the company from $57.00 to $32.00 in a research report on Wednesday, May 1st. The Goldman Sachs Group decreased their target price on 10x Genomics from $30.00 to $26.00 and set a “sell” rating on the stock in a research report on Wednesday, May 1st. Barclays decreased their price objective on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, April 10th. Bank of America decreased their price objective on 10x Genomics from $45.00 to $36.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. Finally, UBS Group decreased their price objective on 10x Genomics from $52.00 to $30.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.50.

Read Our Latest Research Report on TXG

About 10x Genomics

(Get Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Stories

Insider Buying and Selling by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.